Market Cap | 22.63M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -13.31M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 22.00% |
Sales | 37.76M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 6.00% |
Dividend | N/A | Price/Book | 0.31 | EPS next 5Y | - | 52W High Chg | -31.00% |
Recommedations | - | Quick Ratio | 1.86 | Shares Outstanding | 411.07M | 52W Low Chg | 45.00% |
Insider Own | 4.46% | ROA | -7.17% | Shares Float | 382.19M | Beta | 0.89 |
Inst Own | 0.71% | ROE | -24.96% | Shares Shorted/Prior | -/- | Price | 0.06 |
Gross Margin | 35.45% | Profit Margin | -35.25% | Avg. Volume | 105,472 | Target Price | - |
Oper. Margin | -23.38% | Earnings Date | Nov 14 | Volume | 209,553 | Change | 8.61% |
MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.